New cancer drug IDE161 enters human testing
NCT ID NCT05787587
First seen Sep 30, 2025 · Last updated Jun 23, 2026 · Updated 43 times
Summary
This early-stage trial tests a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in 216 adults with advanced solid tumors (like breast, ovarian, or lung cancer). The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. It is for people whose cancer has spread and who have certain genetic changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169, United States
-
Dana Faber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Hoag Memorial Hospital
Newport Beach, California, 92663, United States
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
NEXT Oncology
Irving, Texas, 75039, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
NEXT Oncology
Fairfax, Virginia, 22031, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
START Mountain Region
West Valley City, Utah, 84119, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute - Oklahoma University
Oklahoma City, Oklahoma, 73104, United States
-
Sarah Cannon Research Institute - Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
The Angeles Clinic
Los Angeles, California, 90025, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
-
Weil Cornell University
New York, New York, 10065, United States
-
Yale University
New Haven, Connecticut, 06511, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IDE-161 (PARG inhibitor) and pembrolizumab (immunotherapy)
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors, especially those with certain genetic changes.
What could go wrong
This is an early Phase 1 trial, so safety and dosing are still being figured out. It may not work for all cancer types, and side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.